man som gungar

This is Swelife

Swelife supports collaboration within academia, industry and healthcare, with the goal to strengthen Life Science in Sweden and to improve public health.
It is a strategic innovation programme, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programme’s partners.
Swelife is a facilitator. Through a long-term, national perspective our work aims to contribute to these effects:

  • The knowledge and resources within life science in Sweden are utilised nationally through collaboration and coordination
  • Sweden offers good conditions for sustainable growth and international competitiveness in the life science sector
  • Citizens of Sweden have access to innovative, equal, and people-centred care


Life science in Sweden has a leading role in developments towards world-class health and sustainable growth.


Swelife facilitates and accelerates innovation and collaboration within life science – from ideas to benefits for society.

Budget and Support

More than 100 organisations from healthcare, academia and industry in Sweden currently support Swelife.


  • 2018: SEK 65 million from Vinnova (+SEK 65 million in co-financing)
  • 2017: SEK 55 million from Vinnova (+SEK 55 million in co-financing)
  • 2016: SEK 40 million from Vinnova (+SEK 40 million in co-financing)
  • 2015: SEK 30 million from Vinnova (+SEK 30 million in co-financing)
  • 2014: SEK 9 million from Vinnova (+SEK 9 million in co-financing)


Swelife was established in the summer of 2014 when the Diabetes Agenda and SILS (Sweden as an International Centre for Life Science) jointly applied to launch a so-called strategic innovation area (SIO). The idea was to gather the Life Science regions in Sweden under one common national research and innovation agenda.
The SIO on non-communicable diseases was approved in May 2014, changed its name to Swelife in the autumn, and in January 2015 included an additional agenda (PMC – Personalised Medicine Cancer).

Swelife’s goals 2020

  1. Swelife engages – as a facilitator – stakeholders from the entire life science sector (academia, industry, healthcare and patients)
  2. Swelife has reinforced its international perspective
  3. Swelife has contributed to a national life science strategy
  4. Swelife has contributed to increasing the level of expertise within the life science sector, and to making it accessible
  5. SMEs and early-stage projects have access to more comprehensive financing, from idea to used product/service
  6. Swelife has contributed to better overview of, and access to, research infrastructure related to life science
  7. Swelife has enabled development and national dissemination of generic nationally scalable solutions for improved health
  8. Swelife has contributed to more structured and shareable data